Press Release September 17, 2020

Palleon Pharmaceuticals Raises $100 million Series B to Develop Drugs Targeting Glycan-Mediated Immune Regulation to Treat Cancer and Inflammatory Diseases

The Life Sciences team advised Palleon Pharmaceuticals on its $100 million Series B financing led by Matrix Capital Management, with participation from SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures, AbbVie Ventures, and Surveyor Capital (a Citadel company).
 
Palleon Pharmaceuticals is the leading biotechnology company developing drugs that target glycan-mediated immune regulation to treat cancer and inflammatory diseases. The company’s proprietary platforms integrate technologies and insights from global scientific leaders in the glyco-immunology field to overcome historical scientific hurdles and create novel therapeutics for devastating diseases characterized by immune system dysfunction. The Series B funding will be used to advance Palleon’s pipeline of drug candidates to human clinical trials.
 
The Goodwin team was led by Duncan Greenhalgh, Kingsley Taft, Mulon Luo, Andrew Whitworth, Peter Rodas, and Coleen Doyle.
 
For more details, read the press release and article in Endpoints.